Literature DB >> 18035773

Circulating cytokine profiles in leprosy patients.

Vasudha A Belgaumkar1, Neeta R Gokhale, Pradeep M Mahajan, Renu Bharadwaj, Dakshayani P Pandit, Shantanu Deshpande.   

Abstract

BACKGROUND: Leprosy is a chronic infectious disease caused by Mycobacterium leprae which is an obligate intracellular pathogen. It is characterised by a broad spectrum of clinical forms dictated by the patient's immune response to the organism. The tuberculoid pole has good cell mediated immunity to M. leprae, with few lesions and bacilli while the lepromatous pole has poor immunity coupled with extensive involvement and greater bacillary load.
METHODS: We studied serum levels of interferon gamma and interleukin 6 in 100 patients of untreated leprosy, compared them with 30 age and sex matched normal healthy controls and co-related them with different parts of the spectrum and reactional episodes. The purpose of this study was to delineate the role of cytokines and their clinical implications in the leprosy spectrum and during reactional episodes.
RESULTS: We observed that mean cytokine levels were significantly higher in the patient group as compared to the controls. In the non reactional patient group, pure neuritic leprosy patients showed highest levels of INFgamma which were directly proportional to the extent of nerve involvement. Lepromatous leprosy patients had the highest levels of IL6. Bacteriological index demonstrated a negative and positive corelation with INFgamma and IL 6 levels respectively. Type I and Type II reactional patients had higher levels of INFgamma and IL 6 respectively as compared to nonreactional patients.
CONCLUSIONS: Our results suggest that pure neuritic leprosy and borderline tuberculoid patients in type I reaction are at greatest risk for nerve and tissue damage. Thus cytokines have the potential to play a significant role in classification, prognosis and treatment of leprosy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18035773

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  12 in total

1.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

Authors:  María G Zavala-Cerna; Mary Fafutis-Morris; Cecilia Guillen-Vargas; Mario Salazar-Páramo; Diana E García-Cruz; Carlos Riebeling; Arnulfo Nava
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

2.  Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.

Authors:  Ana Paula Vieira; Maria Ângela Bianconcini Trindade; Carla Pagliari; João Avancini; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Gil Benard
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

3.  Increased serum levels of interleukin-6 in erythema nodosum leprosum suggest its use as a biomarker.

Authors:  Fátima Regina Vilani-Moreno; Vânia Nieto Brito-de-Souza; Sônia Maria Usó Ruiz Silva; Adriana Sierra Assêncio Almeida Barbosa; Beatriz Gomes Carreira Sartori; Ana Paula Campanelli; Jaison Antonio Barreto; Marcos da Cunha Lopes Virmond
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

4.  Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy.

Authors:  Luciana Silva Rodrigues; Mariana Andrea Hacker; Ximena Illarramendi; Maria Fernanda Miguens Castelar Pinheiro; José Augusto da Costa Nery; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani
Journal:  BMC Infect Dis       Date:  2011-12-13       Impact factor: 3.090

5.  Potential plasma markers of Type 1 and Type 2 leprosy reactions: a preliminary report.

Authors:  Mariane M Stefani; Jackeline G Guerra; Ana Lucia M Sousa; Mauricio B Costa; Maria Leide W Oliveira; Celina T Martelli; David M Scollard
Journal:  BMC Infect Dis       Date:  2009-05-27       Impact factor: 3.090

Review 6.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

Review 7.  The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy.

Authors:  Adriana Barbosa de Lima Fonseca; Marise do Vale Simon; Rodrigo Anselmo Cazzaniga; Tatiana Rodrigues de Moura; Roque Pacheco de Almeida; Malcolm S Duthie; Steven G Reed; Amelia Ribeiro de Jesus
Journal:  Infect Dis Poverty       Date:  2017-02-06       Impact factor: 4.520

8.  Single lesion multibacillary leprosy, a treatment enigma: a case report.

Authors:  Bishwa R Sapkota; Kapil D Neupane; Ram K Maharjan
Journal:  J Med Case Rep       Date:  2009-01-13

9.  Use of a T cell interferon gamma release assay in the investigation for suspected active tuberculosis in a low prevalence area.

Authors:  Niclas Winqvist; Per Björkman; Ann Norén; Håkan Miörner
Journal:  BMC Infect Dis       Date:  2009-07-03       Impact factor: 3.090

Review 10.  Inflammatory Mediators of Leprosy Reactional Episodes and Dental Infections: A Systematic Review.

Authors:  D C B Cortela; A L de Souza Junior; M C L Virmond; E Ignotti
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.